Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®).

Kemp TJ, Safaeian M, Hildesheim A, Pan Y, Penrose KJ, Porras C, Schiller JT, Lowy DR, Herrero R, Pinto LA.

Vaccine. 2012 Dec 17;31(1):165-70. doi: 10.1016/j.vaccine.2012.10.067. Epub 2012 Oct 31.

2.

Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, Østergaard L, Søgaard OS.

Hum Vaccin Immunother. 2014;10(5):1147-54. doi: 10.4161/hv.27925. Epub 2014 Feb 19.

3.

Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial.

Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, Lowy DR, Wacholder S, Schiffman M, Rodriguez AC, Herrero R, Kemp T, Shelton G, Quint W, van Doorn LJ, Hildesheim A, Pinto LA; CVT Group.

Cancer Prev Res (Phila). 2013 Nov;6(11):1242-50. doi: 10.1158/1940-6207.CAPR-13-0203. Erratum in: Cancer Prev Res (Phila). 2016 Jan;9(1):116-7.

4.

Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, van der Klis FR.

PLoS One. 2013 Sep 18;8(9):e74797. doi: 10.1371/journal.pone.0074797. eCollection 2013.

5.

Immunogenicity assessment of HPV16/18 vaccine using the glutathione S-transferase L1 multiplex serology assay.

Robbins HA, Waterboer T, Porras C, Kemp TJ, Pawlita M, Rodriguez AC, Wacholder S, Gonzalez P, Schiller JT, Lowy DR, Esser M, Matys K, Poncelet S, Herrero R, Hildesheim A, Pinto LA, Safaeian M.

Hum Vaccin Immunother. 2014;10(10):2965-74. doi: 10.4161/21645515.2014.972811.

6.

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G; HPV-010 Study Group.

Hum Vaccin. 2009 Oct;5(10):705-19. Epub 2009 Oct 14.

PMID:
19684472
7.

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.

Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, Østergaard L, Søgaard OS.

J Infect Dis. 2014 Apr 15;209(8):1165-73. doi: 10.1093/infdis/jit657. Epub 2013 Nov 23.

PMID:
24273179
8.

Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus.

Herrin DM, Coates EE, Costner PJ, Kemp TJ, Nason MC, Saharia KK, Pan Y, Sarwar UN, Holman L, Yamshchikov G, Koup RA, Pang YY, Seder RA, Schiller JT, Graham BS, Pinto LA, Ledgerwood JE.

Hum Vaccin Immunother. 2014;10(12):3446-54. doi: 10.4161/hv.34408.

9.

Cross-neutralizing antibodies elicited by the Cervarix® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities.

Bissett SL, Draper E, Myers RE, Godi A, Beddows S.

Vaccine. 2014 Feb 26;32(10):1139-46. doi: 10.1016/j.vaccine.2014.01.008. Epub 2014 Jan 15.

10.

Correlation between ELISA and pseudovirion-based neutralisation assay for detecting antibodies against human papillomavirus acquired by natural infection or by vaccination.

Zhao H, Lin ZJ, Huang SJ, Li J, Liu XH, Guo M, Zhang J, Xia NS, Pan HR, Wu T, Li CG.

Hum Vaccin Immunother. 2014;10(3):740-6. Epub 2014 Jan 2.

11.

Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.

Barzon L, Squarzon L, Masiero S, Pacenti M, Marcati G, Mantelli B, Gabrielli L, Pascucci MG, Lazzarotto T, Caputo A, Palù G.

Vaccine. 2014 Sep 15;32(41):5357-62. doi: 10.1016/j.vaccine.2014.07.014. Epub 2014 Jul 18.

PMID:
25045814
12.

A comparative study of two different assay kits for the detection of secreted alkaline phosphatase in HPV antibody neutralization assays.

Kemp TJ, Matsui K, Shelton G, Safaeian M, Pinto LA.

Hum Vaccin Immunother. 2015;11(2):337-46. doi: 10.4161/21645515.2014.990851.

13.

Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.

Wang JW, Jagu S, Wang C, Kitchener HC, Daayana S, Stern PL, Pang S, Day PM, Huh WK, Roden RB.

PLoS One. 2014 Jul 7;9(7):e101576. doi: 10.1371/journal.pone.0101576. eCollection 2014.

14.

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, Mast TC, Robinson R, Murphy BR, Karron RA, Dillner J, Schiller JT, Lowy DR.

J Natl Cancer Inst. 2001 Feb 21;93(4):284-92.

PMID:
11181775
15.

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.

16.

Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule.

Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini SL.

Vaccine. 2014 May 30;32(26):3232-6. doi: 10.1016/j.vaccine.2014.04.005. Epub 2014 Apr 13.

17.
18.

Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine.

Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA.

Vaccine. 2010 Jul 26;28(33):5407-13. doi: 10.1016/j.vaccine.2010.06.018. Epub 2010 Jun 17.

19.

Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial.

Krajden M, Cook D, Yu A, Chow R, Su Q, Mei W, McNeil S, Money D, Dionne M, Palefsky J, Karunakaran K, Kollmann T, Ogilvie G, Petric M, Dobson S.

Vaccine. 2014 Jan 23;32(5):624-30. doi: 10.1016/j.vaccine.2013.09.007. Epub 2013 Sep 19.

20.

Cross-protective vaccine efficacy of the bivalent HPV vaccine against HPV31 is associated with humoral immune responses: results from the Costa Rica Vaccine Trial.

Safaeian M, Kemp TJ, Pan DY, Porras C, Rodriguez AC, Schiffman M, Cortes B, Katki H, Wacholder S, Schiller JT, Gonzalez P, Penrose K, Lowy DR, Quint W, van Doorn LJ, Herrero R, Hildesheim A, Pinto LA.

Hum Vaccin Immunother. 2013 Jul;9(7):1399-406. doi: 10.4161/hv.24340. Epub 2013 Apr 9.

Supplemental Content

Support Center